Natixis Advisors LLC Has $5.12 Million Position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Natixis Advisors LLC lowered its stake in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 34.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 332,923 shares of the company's stock after selling 171,611 shares during the period. Natixis Advisors LLC's holdings in Teva Pharmaceutical Industries were worth $5,117,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Orion Portfolio Solutions LLC boosted its stake in Teva Pharmaceutical Industries by 11.9% in the fourth quarter. Orion Portfolio Solutions LLC now owns 12,302 shares of the company's stock valued at $271,000 after acquiring an additional 1,310 shares during the last quarter. Wellington Management Group LLP boosted its stake in Teva Pharmaceutical Industries by 2.1% in the fourth quarter. Wellington Management Group LLP now owns 185,912 shares of the company's stock valued at $4,098,000 after acquiring an additional 3,816 shares during the last quarter. Trexquant Investment LP bought a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $2,092,000. Resona Asset Management Co. Ltd. bought a new position in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $7,211,000. Finally, Russell Investments Group Ltd. boosted its stake in Teva Pharmaceutical Industries by 33.8% in the fourth quarter. Russell Investments Group Ltd. now owns 204,447 shares of the company's stock valued at $4,506,000 after acquiring an additional 51,601 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Up 0.2%

Shares of NYSE:TEVA opened at $15.72 on Wednesday. The company's 50-day moving average price is $16.80 and its two-hundred day moving average price is $16.51. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.06 and a quick ratio of 0.77. Teva Pharmaceutical Industries Ltd. has a one year low of $12.47 and a one year high of $22.80. The stock has a market capitalization of $18.03 billion, a PE ratio of -98.25, a price-to-earnings-growth ratio of 0.93 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The firm had revenue of $4.18 billion for the quarter, compared to analysts' expectations of $4.34 billion. During the same period in the previous year, the firm posted $0.61 EPS. The company's revenue for the quarter was up .3% on a year-over-year basis. On average, equities analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Analyst Ratings Changes

TEVA has been the topic of a number of recent research reports. Wall Street Zen raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Hsbc Global Res raised shares of Teva Pharmaceutical Industries to a "strong-buy" rating in a research note on Monday, April 28th. UBS Group reduced their price target on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research report on Thursday, June 26th. The Goldman Sachs Group started coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They set a "buy" rating and a $24.00 price target on the stock. Finally, Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $24.71.

Insiders Place Their Bets

In other news, insider Placid Jover sold 6,053 shares of the company's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $91,763.48. Following the sale, the insider directly owned 6,774 shares of the company's stock, valued at approximately $102,693.84. This represents a 47.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the completion of the sale, the executive vice president directly owned 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,001 shares of company stock valued at $996,958 in the last three months. 0.55% of the stock is currently owned by corporate insiders.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.